Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Refined karyotype-based prognostic stratification of chronic lymphocytic leukemia with a low- and very-low-risk genetic profile

Leukemia volume 32, pages 543–546 (2018)Cite this article

Subjects

Clonal mutations of the TP53, NOTCH1, SF3B1 or BIRC3 genes have allowed to refine the conventional fluorescence in situ hybridization (FISH)-based prognostic stratification of chronic lymphocytic leukemia (CLL) by reclassifying ∼20% of good-risk patients (del13q, +12, normal FISH) into higher-risk subgroups.1 Consequently, two novel CLL good-risk subgroups, both devoid of the four gene clonal mutations, have been defined: low risk—harboring +12 or a normal FISH (10-year overall survival (OS): 57%)—and very-low risk—carrying del13q only, whose 10-year OS (69.3%) does not differ from that of the healthy age-matched general population.1

Cytogenetics using novel mitogens allows to recognize chromosomal aberrations in regions uncovered by standard FISH and to identify novel genetic subgroups with prognostic relevance, especially within CLL carrying del17p.2, 3, 4, 5 Less is known about the integration of karyotype (KT)-based subgroups into the good-risk CLL categories.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Rossi D, Rasi S, Spina V, Bruscaggin A, Monti S, Ciardullo C et al. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood 2013; 121: 1403–1412.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Rigolin GM, Cibien F, Martinelli S, Formigaro L, Rizzotto L, Tammiso E et al. Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia with ‘normal’ FISH: correlations with clinicobiologic parameters. Blood 2012; 119: 2310–2313.

    Article  CAS  PubMed  Google Scholar 

  3. Delgado J, Salaverria I, Baumann T, Martínez-Trillos A, Lee E, Jiménez L et al. Genomic complexity and IGHV mutational status are key predictors of outcome of chronic lymphocytic leukemia patients with TP53 disruption. Haematologica 2014; 99: e231–e234.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Blanco G, Puiggros A, Baliakas P, Athanasiadou A, García-Malo M, Collado R et al. Karyotypic complexity rather than chromosome 8 abnormalities aggravates the outcome of chronic lymphocytic leukemia patients with TP53 aberrations. Oncotarget 2016; 7: 80916–80924.

    PubMed  PubMed Central  Google Scholar 

  5. Yu L, Kim HT, Kasar SN, Benien P, Du W, Hoang K et al. Survival of Del17p CLL depends on genomic complexity and somatic mutation. Clin Cancer Res 2017; 23: 735–745.

    Article  CAS  PubMed  Google Scholar 

  6. Rigolin GM, Saccenti E, Rizzotto L, Ferracin M, Martinelli S, Formigaro L et al. Genetic subclonal complexity and miR125a-5p down-regulation identify a subset of patients with inferior outcome in low-risk CLL patients. Oncotarget 2014; 5: 140–149.

    Article  PubMed  Google Scholar 

  7. Rossi D, Khiabanian H, Spina V, Ciardullo C, Bruscaggin A, Famà R et al. Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia. Blood 2014; 123: 2139–2147.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Haferlach C, Dicker F, Schnittger S, Kern W, Haferlach T . Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgV(H) status and immunophenotyping. Leukemia 2007; 21: 2442–2451.

    Article  CAS  PubMed  Google Scholar 

  9. Haferlach C, Dicker F, Weiss T, Schnittger S, Beck C, Grote-Metke A et al. Toward a comprehensive prognostic scoring system in chronic lymphocytic leukemia based on a combination of genetic parameters. Genes Chromosomes Cancer 2010; 49: 851–859.

    CAS  PubMed  Google Scholar 

  10. Baliakas P, Iskas M, Gardiner A, Davis Z, Plevova K, Nguyen-Khac F et al. Chromosomal translocations and karyotype complexity in chronic lymphocytic leukemia: a systematic reappraisal of classic cytogenetic data. Am J Hematol 2014; 89: 249–255.

    Article  CAS  PubMed  Google Scholar 

  11. Rigolin GM, Saccenti E, Bassi C, Lupini L, Quaglia FM, Cavallari M et al. Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: clinical and biological correlations. J Hematol Oncol 2016; 9: 88.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Foà R, Del Giudice I, Cuneo A, Del Poeta G, Ciolli S, Di Raimondo F et al. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. Am J Hematol 2014; 89: 480–486.

    Article  PubMed  Google Scholar 

  13. Herling CD, Klaumünzer M, Rocha CK, Altmüller J, Thiele H, Bahlo J et al. Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy. Blood 2016; 128: 395–404.

    Article  CAS  PubMed  Google Scholar 

  14. Badoux XC, Keating MJ, Wang X, O'Brien SM, Ferrajoli A, Faderl S et al. Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood 2011; 117: 3016–3024.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Thompson PA, O'Brien SM, Wierda WG, Ferrajoli A, Stingo F, Smith SC et al. Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens. Cancer 2015; 121: 3612–3621.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors thank Associazione Italiana per la Ricerca sul Cancro (AIRC), Special Program Molecular Clinical Oncology, 5 × 1000, Milan, Italy (MCO-10007) (RF, GG); Ricerca finalizzata RF-2011-02349712 (GMR, AC, GG and RF); Finanziamento Medi Progetti Universitari 2013, Sapienza University, C26A13CCJ4 (IDG); Finanziamento Medi Progetti Universitari 2014, Sapienza University, C26A14WWA9 (IDG); Progetti di Rilevante Interesse Nazionale (PRIN) 2015ZMRFEA (RF, GG and AC); FAR (Fondo di Ateneo per la Ricerca) 2013, 2014, 2016 of the University of Ferrara (GMR, AC); EV and ES are supported by AIL (Associazione Italiana contro le Leucemie Linfomi e Mieloma, Ferrara); NIH funding, U54CA209997 and U54 CA193313 (RR); Grant No. KFS-3746-08-2015, Swiss Cancer League, Bern, Switzerland and Grant No. 320030_169670/1 Swiss National Science Foundation, Berne, Switzerland (DR).

Author information

Author notes

  1. I Del Giudice, G M Rigolin, A Cuneo and R Foà: These authors contributed equally to this work.

Authors and Affiliations

  1. Department of Cellular Biotechnologies and Hematology, Hematology, Policlinico Umberto I, Sapienza University, Rome, Italy

    I Del Giudice, S Raponi, L Cafforio, C Ilari, M Marinelli, M Nanni, S Tavolaro, M Filetti, F R Mauro & R Foà

  2. Hematology Section, Azienda Ospedaliera Universitaria Arcispedale S. Anna, University of Ferrara, Ferrara, Italy

    G M Rigolin, A Bardi, E Tammiso, E Volta, M Negrini, E Saccenti & A Cuneo

  3. Divisions of Life Science and Biomedical Engineering, Hong Kong University of Science and Technology, Hong Kong, China

    J Wang

  4. Department of Biomedical Informatics, Center for Computational Biology and Bioinformatics, Columbia University, New York, NY, USA

    M Bordyuh & R Rabadan

  5. GIMEMA Data Centre, GIMEMA Foundation, Rome, Italy

    A Piciocchi

  6. Hematology, Oncology Institute of Southern Switzerland and Institute of Oncology Research, Bellinzona, Switzerland

    D Rossi

  7. Department of Translational Medicine, Hematology, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy

    G Gaidano

  8. Department of Molecular Medicine, Sapienza University, Rome, Italy

    A Guarini

Authors
  1. I Del Giudice
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G M Rigolin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S Raponi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L Cafforio
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C Ilari
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M Bordyuh
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A Piciocchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. M Marinelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. M Nanni
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. S Tavolaro
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. M Filetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. A Bardi
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. E Tammiso
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. E Volta
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. M Negrini
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. E Saccenti
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. F R Mauro
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. D Rossi
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. G Gaidano
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. A Guarini
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. R Rabadan
    View author publications

    You can also search for this author in PubMed Google Scholar

  23. A Cuneo
    View author publications

    You can also search for this author in PubMed Google Scholar

  24. R Foà
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R Foà.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on the Leukemia website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Giudice, I., Rigolin, G., Raponi, S. et al. Refined karyotype-based prognostic stratification of chronic lymphocytic leukemia with a low- and very-low-risk genetic profile. Leukemia 32, 543–546 (2018). https://doi.org/10.1038/leu.2017.292

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2017.292

Search

Advanced search

Quick links